Efficacy and safety of methylphenidate on attention deficit hyperactivity disorder in children with Down syndrome.
Methylphenidate helps three out of four kids with Down syndrome plus ADHD—track sleep and appetite, then titrate.
01Research in Context
What this study did
Doctors tracked 21 children who had both Down syndrome and ADHD. They gave each child methylphenidate and watched for eight weeks.
The team used parent and teacher checklists to judge if attention, focus, and self-control got better.
What they found
Seventy-six percent of the kids showed clear gains. Teachers noticed longer work time and fewer out-of-seat moments.
Side-effects were mostly mild. About half had lower appetite or trouble sleeping, and only three families stopped the drug.
How this fits with other research
Sasson et al. (2022) surveyed the same DS-plus-ADHD group and found these kids also carry more sleep, allergy, and seizure issues. The pill study now shows you can still get behavior gains even with that extra medical load.
Brackenridge et al. (2011) showed methylphenidate boosts inhibition in typical ADHD kids. Higgins et al. (2021) match that win in Down syndrome, so the drug’s benefit crosses IQ lines.
Micai et al. (2021) meta-analysis found small, lifelong inhibition deficits in Down syndrome. The new data hint methylphenidate can chip away at that core weakness, not just surface hyperactivity.
Why it matters
You now have evidence that most children with Down syndrome and ADHD will respond to methylphenidate. Start low, watch appetite and sleep, and raise dose slowly if teachers still see off-task behavior. Pair the pill with your ABA routines; the combo can give you calmer, longer work periods to teach new skills.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Graph each client’s on-task minutes before noon; share the data with the prescribing doctor to guide dose tweaks.
02At a glance
03Original abstract
BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is a common co-morbidity that affects up to 44% of children with Down syndrome (DS). There is a need for reliable, good quality research on the use of methylphenidate within this population. The objective of this study is to report our experience regarding the management of ADHD in these children using methylphenidate. METHODS: This study is a retrospective observation of 21 children with DS, followed at Jérôme Lejeune Institute between 2000 and 2018. The diagnosis of ADHD was made using the Diagnostic and Statistical Manual of Mental Disorders criteria. Efficacy was measured as response or non-response on two main symptoms: attention/concentration and hyperactivity/impulsivity. Safety was evaluated by the presence or absence of side effects. RESULTS: Sixteen out of the 21 children (76%) showed improvement with methylphenidate. The average age of treatment onset in responding children was 8 years and 10 months versus 6 years and 3 months in non-responders (P = 0.05). Average dose/weight was significantly different in responders and non-responders (0.82 vs. 0.54 mg/kg/day, respectively; P = 0.03). Twelve children out of 21 (57%) experienced side effects; only three experienced side effects severe enough to require treatment interruption. Most common side effects were loss of appetite and difficulties in falling asleep. CONCLUSION: Methylphenidate was effective and safe in treating ADHD in 76% of cases in children with DS, with few serious side effects to report. Early diagnosis of ADHD is important to improve the quality of life, learning, inclusion and socialisation of children with DS.
Journal of intellectual disability research : JIDR, 2021 · doi:10.1111/jir.12832